Healthcare advertisers are increasingly looking to connect media exposure with real-world outcomes rather than relying on campaign-level performance reports. The Trade Desk is expanding integrations with healthcare analytics providers Veeva Crossix and IQVIA Digital to bring more granular measurement signals into programmatic media decisioning, allowing pharmaceutical advertisers to use campaign insights while campaigns are still running.
For pharmaceutical marketers, knowing that a campaign performed well is only part of the measurement challenge. The harder question is determining which audiences, devices, geographies and media environments contributed to that performance—and then acting on those signals quickly.
The Trade Desk is attempting to close that gap through expanded integrations with Veeva Crossix and IQVIA Digital, bringing specialized healthcare measurement closer to the platform’s media optimization and bidding workflows.
Traditionally, pharma analytics has often operated alongside media buying platforms. Advertisers could evaluate campaign results and identify optimization opportunities, but applying those insights to an active media campaign could require additional processes.
The expanded integrations are designed to shorten that feedback loop.
For example, a pharmaceutical advertiser could examine audience quality by site, geography or device, connect media exposure with metrics such as new-to-brand prescriptions (NBRx), and use those signals to inform ongoing media allocation.
Crossix is expanding its in-platform optimization capabilities within The Trade Desk. Advertisers can currently optimize campaigns around Audience Quality (AQ) and cost per target reach, while Gross NBRx optimization is planned for the fourth quarter. A weighted KPI capability is also expected in Q4, allowing advertisers to combine Crossix Audience Quality and Gross Conversion data when optimizing toward multiple campaign outcomes.
That development reflects a broader movement in programmatic advertising toward outcome-based optimization. Rather than treating impressions or reach as the final measurement layer, advertisers are increasingly looking for signals that connect media exposure to business or downstream outcomes.
IQVIA Digital is taking a somewhat different role by expanding the granularity of performance measurement. The company plans to introduce AQ measurement across individual sites, geographies and device types, alongside new-to-brand prescription measurement.
The distinction matters for media buyers managing large programmatic campaigns. A campaign may generate strong aggregate results while performance varies considerably across individual supply environments or audience segments. More granular measurement can potentially give traders and automated systems additional signals for deciding where future impressions should be purchased.
The Trade Desk also supports multi-provider HCP decisioning, allowing advertisers to extend National Provider Identifier (NPI) reach across multiple healthcare data providers. The objective is to give pharma advertisers additional scale while maintaining healthcare-specific data controls.
The development places The Trade Desk within a specialized part of the programmatic ecosystem where privacy, data governance and measurement complexity are particularly important. Healthcare advertising cannot simply apply consumer advertising models without accounting for sensitive data and regulatory requirements.
The bigger shift is toward bringing measurement and activation closer together. Instead of waiting until a campaign ends to determine what worked, advertisers can increasingly feed validated performance signals back into media decisioning while campaigns remain active.
For enterprise pharma teams, the value will ultimately depend on data quality, measurement methodology, interoperability and the ability to translate healthcare outcomes into reliable optimization signals. But the direction is clear: specialized healthcare analytics is becoming increasingly connected to the systems responsible for buying and optimizing media.
Market Landscape
Programmatic advertising is evolving from impression-based optimization toward increasingly sophisticated outcome and audience-quality signals. This is particularly visible in verticals such as healthcare, where advertisers need specialized datasets and measurement methodologies.
The Trade Desk’s integrations with Crossix and IQVIA Digital illustrate a broader trend toward closed-loop media measurement: data is collected from campaign activity, translated into performance signals and returned to the buying environment for optimization.
Large advertising ecosystems including Google, Amazon and Microsoft are also investing in automated bidding, measurement and first-party data capabilities. Specialist healthcare providers add another layer by supplying domain-specific signals that general-purpose advertising platforms may not provide.
For pharmaceutical advertisers, interoperability will remain central. The ability to combine multiple measurement providers, define campaign-specific KPIs and optimize against meaningful outcomes could reduce the distance between media buying and business measurement, provided privacy and governance requirements are maintained.
Top Insights
- The Trade Desk is expanding healthcare data integrations with Veeva Crossix and IQVIA Digital to bring measurement signals closer to programmatic media decisioning.
- Crossix enables optimization around Audience Quality and cost per target reach, with Gross NBRx and weighted KPI capabilities planned for Q4.
- IQVIA Digital is expanding measurement granularity across sites, geographies and devices while adding new-to-brand prescription measurement.
- Multi-provider HCP decisioning gives pharmaceutical advertisers additional options for extending NPI reach across healthcare data providers.
- The development reflects a broader AdTech shift toward closed-loop optimization, where campaign measurement can directly inform active media buying decisions.
Get in touch with our Adtech experts
